In the Claims

1-10. (canceled)

11. (currently amended) A method for ~~the treatment of liver fibrotic inflammatory and/or liver autoimmune diseases~~ reducing serum alanine aminotransferase (ALT) in a subject with hepatitis comprising the administration of an effective amount of a CC-chemokine mutant having reduced glycosaminoglycan (GAG)-binding ~~GAG-binding~~ activity to a patient, wherein the CC-chemokine mutant is ~~CCL3 / MIP-1alpha, CCL4 / MIP-1beta, or CCL5 / RANTES~~ a triple 40's CCL5/RANTES (Regulated upon Activation, Normal T-cell Expressed and Presumably Secreted) mutant.

12. (currently amended) The method according to claim 11, wherein ~~the CC-chemokine is CCL5 / RANTES and~~ the mutant comprises SEQ ID NO: 1 ~~is triple 40's RANTES mutant (SEQ ID NO: 1)~~.

13-19 (canceled).

20. (currently amended) The method according to claim 11, wherein the ~~CC-chemokine~~ mutant further comprises ~~an amino acid sequence belonging to a protein sequence other than the corresponding CC-chemokine~~ immunoglobulin constant region.

21. (currently amended) The method according to claim 11, wherein the ~~CC-chemokine~~ mutant is in the form of an active precursor, salt, derivative, conjugate or complex.

22. (currently amended) The method according to claim 11, wherein the ~~liver disease is an alcoholic liver disease, a viral hepatitis, or~~ hepatitis is an autoimmune hepatitis.

23 (new). The method according to claim 11, further comprising the measurement of serum ALT levels in said patient.

24. (new) A method for reducing serum alanine aminotransferase (ALT) levels in a patient comprising measuring serum ALT levels in the patient and administering an effective amount of a CC-chemokine mutant having reduced glycosaminoglycan (GAG)-binding activity to a patient, wherein the CC-chemokine mutant is a triple 40's CCL5/RANTES (Regulated upon Activation, Normal T-cell Expressed and Presumably Secreted) mutant.

25. (new) The method according to claim 24, wherein the mutant comprises SEQ ID NO: 1.

26. (new) The method according to claim 24, wherein the mutant further comprises immunoglobulin constant region.